CTH122

CTH122 is a preclinical-stage small molecule neuroplasticity modulator being developed by Connecta Therapeutics. It is designed to treat neurodevelopmental disorders and chronic pain conditions by modulating neurotrophic factor pathways. The drug aims to address neuroplasticity imbalances, which are characterized by abnormalities in protein networks involved in synaptic and structural plasticity. Preclinical studies have demonstrated efficacy in models of Fragile X Syndrome, Rett syndrome, and neuropathic pain. Unlike Connecta's lead candidate CTH120, which specifically targets the tropomyosin receptor kinase B (TrkB), the precise molecular target of CTH122 has not been publicly disclosed, though it operates within the broader neurotrophic factor signaling network to restore functional connectivity.